226 related articles for article (PubMed ID: 9865705)
1. Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group.
Aapro M
Semin Oncol; 1998 Oct; 25(5 Suppl 12):7-11. PubMed ID: 9865705
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel vs doxorubicin in metastatic breast cancer resistant to alkylating chemotherapy.
Chan S
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):19-24. PubMed ID: 9364537
[TBL] [Abstract][Full Text] [Related]
3. Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results.
Nabholtz JM; Crown J
Semin Oncol; 1998 Dec; 25(6 Suppl 13):4-9. PubMed ID: 9865685
[TBL] [Abstract][Full Text] [Related]
4. Single-agent docetaxel (Taxotere) in randomized phase III trials.
Burris HA
Semin Oncol; 1999 Jun; 26(3 Suppl 9):1-6. PubMed ID: 10426452
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel (Taxotere) in combination with anthracyclines in the treatment of breast cancer.
Nabholtz JM; North S; Smylie M; Mackey J; Au HJ; Au R; Morrish D; Salter E; Tonkin K
Semin Oncol; 2000 Apr; 27(2 Suppl 3):11-8. PubMed ID: 10810933
[TBL] [Abstract][Full Text] [Related]
6. A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer.
Crown J
Semin Oncol; 1999 Feb; 26(1 Suppl 3):5-9. PubMed ID: 10203264
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer.
Nabholtz JM
Semin Oncol; 1999 Jun; 26(3 Suppl 9):7-13. PubMed ID: 10426453
[TBL] [Abstract][Full Text] [Related]
8. Evolution in the treatment of advanced breast cancer.
Crown J
Semin Oncol; 1998 Oct; 25(5 Suppl 12):12-7. PubMed ID: 9865706
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer.
van Oosterom AT
Semin Oncol; 1995 Dec; 22(6 Suppl 13):22-8. PubMed ID: 8604449
[TBL] [Abstract][Full Text] [Related]
10. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
Chan S; Friedrichs K; Noel D; Pintér T; Van Belle S; Vorobiof D; Duarte R; Gil Gil M; Bodrogi I; Murray E; Yelle L; von Minckwitz G; Korec S; Simmonds P; Buzzi F; González Mancha R; Richardson G; Walpole E; Ronzoni M; Murawsky M; Alakl M; Riva A; Crown J;
J Clin Oncol; 1999 Aug; 17(8):2341-54. PubMed ID: 10561296
[TBL] [Abstract][Full Text] [Related]
11. Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies.
Sparano JA
Semin Oncol; 1998 Dec; 25(6 Suppl 13):10-5. PubMed ID: 9865686
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel vs mitomycin plus vinblastine in anthracycline-resistant metastatic breast cancer.
Nabholtz JM; Thuerlimann B; Bezwoda WR; Melnychuk D; Deschênes L; Douma J; Vandenberg TA; Rapoport B; Rosso R; Trillet-Lenoir V; Drbal J; Aapro MS; Alaki M; Murawsky M; Riva A
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):25-30. PubMed ID: 9364538
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
14. Phase III randomized trials of docetaxel in patients with metastatic breast cancer.
Crown J
Semin Oncol; 1999 Jun; 26(3 Suppl 8):33-8. PubMed ID: 10403472
[TBL] [Abstract][Full Text] [Related]
15. Phase I-II studies of docetaxel as a single agent in the treatment of metastatic breast cancer.
Trudeau ME
Semin Oncol; 1999 Jun; 26(3 Suppl 8):21-6. PubMed ID: 10403470
[TBL] [Abstract][Full Text] [Related]
16. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
Alba E; Martín M; Ramos M; Adrover E; Balil A; Jara C; Barnadas A; Fernández-Aramburo A; Sánchez-Rovira P; Amenedo M; Casado A;
J Clin Oncol; 2004 Jul; 22(13):2587-93. PubMed ID: 15226326
[TBL] [Abstract][Full Text] [Related]
17. Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer.
Ravdin PM; Valero V
Semin Oncol; 1995 Apr; 22(2 Suppl 4):17-21. PubMed ID: 7740326
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel/doxorubicin/cyclophosphamide in the treatment of metastatic breast cancer.
Nabholtz JM; Smylie M; Mackey JR; Noel D; Paterson AH; al-Tweigeri T; Au D; Sansregret E; Delorme F; Riva A
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):37-41. PubMed ID: 9364541
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel (Taxotere) in combination: a step forward.
Burris HA; Fields S; Peacock N
Semin Oncol; 1995 Dec; 22(6 Suppl 13):35-40. PubMed ID: 8604452
[TBL] [Abstract][Full Text] [Related]
20. Taxanes in combination with doxorubicin in the treatment of metastatic breast cancer.
Dieras V
Semin Oncol; 1998 Oct; 25(5 Suppl 12):18-22. PubMed ID: 9865707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
